newsfilter
← Latest News
GlobeNewswire·

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI® 3Q 2026 net product